Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Mivavotinib
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Mivavotinib TAK-659|TAK659 SYK Inhibitor 14 Mivavotinib (TAK-659) is an inhibitor of spleen tyrosine kinase (SYK), which may lead to B-cell inhibition and antitumor activity (PMID: 32327472).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown chronic lymphocytic leukemia not applicable Mivavotinib Case Reports/Case Series Actionable In a Phase I trial, Mivavotinib (TAK-659) treatment resulted in an objective response rate of 60% (3/5, 3 partial responses) in patients with relapsed or refractory chronic lymphocytic leukemia, with a median duration of response not reached (PMID: 32327472; NCT02000934). 32327472
Unknown unknown lymphoma not applicable Mivavotinib Phase I Actionable In a Phase I trial, Mivavotinib (TAK-659) treatment resulted in an objective response rate of 40% (27/67, 12 complete responses, 15 partial responses) in patients with relapsed or refractory diffuse large B-cell lymphoma, with a median duration of response of 856 days (PMID: 32327472; NCT02000934). 32327472
Unknown unknown follicular lymphoma not applicable Mivavotinib Case Reports/Case Series Actionable In a Phase I trial, Mivavotinib (TAK-659) treatment resulted in an objective response rate of 89% (8/9, 2 complete responses, 6 partial responses) in patients with relapsed or refractory follicular lymphoma, with a median duration of response of 137 days (PMID: 32327472; NCT02000934). 32327472
Unknown unknown diffuse large B-cell lymphoma not applicable Mivavotinib Phase I Actionable In a Phase I trial, Mivavotinib (TAK-659) treatment resulted in an objective response rate of 28% (12/43, 8 complete responses, 4 partial responses) in patients with relapsed or refractory diffuse large B-cell lymphoma, with a median duration of response not reached (PMID: 32327472; NCT02000934). 32327472
Unknown unknown mantle cell lymphoma not applicable Mivavotinib Case Reports/Case Series Actionable In a Phase I trial, Mivavotinib (TAK-659) treatment resulted in an objective response rate of 33% (1/3, 1 partial responses) in patients with relapsed or refractory mantle cell lymphoma, with a median duration of response of 109 days (PMID: 32327472; NCT02000934). 32327472
Unknown unknown non-Hodgkin lymphoma not applicable Mivavotinib Case Reports/Case Series Actionable In a Phase I trial, Mivavotinib (TAK-659) treatment resulted in an objective response rate of 73% (11/15, 4 complete responses, 7 partial responses) in patients with relapsed or refractory indolent non-Hodgkin lymphoma, with a median duration of response of 176 days (PMID: 32327472; NCT02000934). 32327472

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03359733 Phase I Mivavotinib A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor Withdrawn USA 0
NCT03123393 Phase II Mivavotinib TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Terminated USA | CAN 4
NCT02551055 Phase I Docetaxel Paclitaxel Alisertib Mivavotinib MLN1117 MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma Terminated USA 1
NCT02000934 Phase I Mivavotinib A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies Active, not recruiting USA 3
NCT02323113 Phase Ib/II Mivavotinib Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) Completed USA | CAN 0


Additional content available in CKB BOOST